1
|
Vladimirova A, Onishi Y, Kloc K, Rémuzat C, Toumi M. PNS26 Real-World Evidence in Regulatory Decision-Making: Parallel between FDA in the US and Pmda in JAPAN. Value Health Reg Issues 2020. [DOI: 10.1016/j.vhri.2020.07.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Tomaszek E, Kapusniak A, Rémuzat C, Onishi Y, Toumi M. PIN36 Comparison of Vaccine Market Access Pathways in European and Asian Countries. Value Health Reg Issues 2020. [DOI: 10.1016/j.vhri.2020.07.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Caban A, Pisarczyk K, Kopacz K, Kapuśniak A, Toumi M, Rémuzat C, Kornfeld A. Filling the gap in CNS drug development: evaluation of the role of drug repurposing. J Mark Access Health Policy 2017; 5:1299833. [PMID: 28473889 PMCID: PMC5405562 DOI: 10.1080/20016689.2017.1299833] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 02/15/2017] [Indexed: 06/07/2023]
Abstract
Background and objective: Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs. Little is known and documented regarding the efficiency of repurposing strategies in drug development. The objective of this article is to assess the extent and meaning of this process in the CNS area. Methods: In order to identify repurposed drugs that target the CNS, an extensive search was performed. For each identified case, its initial and target indication, development status and the type of repurposing strategy (repositioning, reformulation or both) was recorded. Results: One hundred and eighteen source products were identified. They were repurposed (mainly repositioned) 203 times with 81 products repurposed once and 38 products repurposed twice or more. The highest number of source drugs originated from the CNS area. Alzheimer's disease was targeted most often. Half of the new indications were approved. Regarding repurposing within the CNS area, epilepsy, schizophrenia and depression were the richest sources of repurposed drugs. Conclusions: Repurposing drugs into CNS is an efficient and very active drug development method, exemplified by the considerable number of new indications that have been found via this strategy, with approximately half of the target indications currently under development.
Collapse
Affiliation(s)
- A. Caban
- Creativ-Ceutical, Pricing & Market Access Department, Krakow, Poland
| | - K. Pisarczyk
- Creativ-Ceutical, Pricing & Market Access Department, Krakow, Poland
| | - K. Kopacz
- Creativ-Ceutical, Pricing & Market Access Department, Krakow, Poland
| | - A. Kapuśniak
- Creativ-Ceutical, Pricing & Market Access Department, Krakow, Poland
| | - M. Toumi
- Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France
| | - C. Rémuzat
- Creativ-Ceutical, Pricing & Market Access Department, Paris, France
| | - A. Kornfeld
- Creativ-Ceutical, Pricing & Market Access Department, Paris, France
| |
Collapse
|
4
|
Tavella F, Korchagina D, Rodrigues J, Rémuzat C. Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In Italy. Value Health 2014; 17:A540. [PMID: 27201733 DOI: 10.1016/j.jval.2014.08.1733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
5
|
Korchagina D, Rémuzat C, Rodrigues J, Kornfeld A, Toumi M. Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In France. Value Health 2014; 17:A540. [PMID: 27201738 DOI: 10.1016/j.jval.2014.08.1734] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | | | | | - M Toumi
- University of Marseille, Marseille, France
| |
Collapse
|
6
|
Refaï T, Millier A, Rémuzat C, Toumi M. Public Beliefs and Attitudes about Schizophrenia, Major Depression and Psychotropic Medication in Tunisia. Value Health 2014; 17:A770-A771. [PMID: 27202838 DOI: 10.1016/j.jval.2014.08.314] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- T Refaï
- Creativ-Ceutical, Tunis, Tunisia
| | | | - C Rémuzat
- Creativ-Ceutical France, Paris, France
| | - M Toumi
- University of Marseille, Marseille, France
| |
Collapse
|
7
|
Thivolet M, Cetinsoy L, Vataire AL, Rémuzat C, Brunet J, Kornfeld A, Toumi M. External Reference Pricing Impact of the Integration of the Amnog Discount In The List Price. Value Health 2014; 17:A423. [PMID: 27201081 DOI: 10.1016/j.jval.2014.08.1046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | | | | | - J Brunet
- Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | | | - M Toumi
- University Aix-Marseille, Marseille, France
| |
Collapse
|
8
|
Affiliation(s)
| | | | - D Urbinati
- Creativ-Ceutical, Luxembourg, Luxembourg
| | - M Toumi
- University Aix-Marseille, Marseille, France
| |
Collapse
|
9
|
Young KE, Rémuzat C, Urbinati D, Toumi M. An Overview of the Biosimilar Market in the Us. Value Health 2014; 17:A410. [PMID: 27201005 DOI: 10.1016/j.jval.2014.08.968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | - D Urbinati
- Creativ-Ceutical, Luxembourg, Luxembourg
| | - M Toumi
- University Aix-Marseille, Marseille, France
| |
Collapse
|
10
|
Rodrigues J, Korchagina D, Rémuzat C, Brunet J, Tavella F. Orphan Drug Approvals In Europe: Historical Review and Trends. Value Health 2014; 17:A539. [PMID: 27201731 DOI: 10.1016/j.jval.2014.08.1731] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | | | - J Brunet
- Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | | |
Collapse
|
11
|
Korchagina D, Tavella F, Rémuzat C, Kornfeld A, Toumi M. Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy. Value Health 2014; 17:A539-A540. [PMID: 27201730 DOI: 10.1016/j.jval.2014.08.1732] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | | | | | - M Toumi
- University of Marseille, Marseille, France
| |
Collapse
|